Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analysis from phase 3 trials in patients with psoriatic arthritis
Secukinumab showed consistent and sustained efficacy in clearing nail psoriasis in patients with psoriatic arthritis, with or without axial manifestations, irrespective of severity of nail involvement. Reduction of nail disease was also associated with response across all musculoskeletal and skin ma...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Wiley
2022
|
| _version_ | 1797109747897335808 |
|---|---|
| author | Reich, K Baraliakos, X Coates, LC Elewski, B Bao, W Kasparek, T Gaillez, C Pournara, E Aassi, M Perella, C Gottlieb, AB |
| author_facet | Reich, K Baraliakos, X Coates, LC Elewski, B Bao, W Kasparek, T Gaillez, C Pournara, E Aassi, M Perella, C Gottlieb, AB |
| author_sort | Reich, K |
| collection | OXFORD |
| description | Secukinumab showed consistent and sustained efficacy in clearing nail psoriasis in patients with psoriatic arthritis, with or without axial manifestations, irrespective of severity of nail involvement. Reduction of nail disease was also associated with response across all musculoskeletal and skin manifestations of psoriatic arthritis. |
| first_indexed | 2024-03-07T07:45:48Z |
| format | Journal article |
| id | oxford-uuid:ac1ecf16-b2cd-4e49-82e2-e828f551732f |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:45:48Z |
| publishDate | 2022 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:ac1ecf16-b2cd-4e49-82e2-e828f551732f2023-06-07T08:00:53ZSecukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analysis from phase 3 trials in patients with psoriatic arthritisJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ac1ecf16-b2cd-4e49-82e2-e828f551732fEnglishSymplectic ElementsWiley2022Reich, KBaraliakos, XCoates, LCElewski, BBao, WKasparek, TGaillez, CPournara, EAassi, MPerella, CGottlieb, ABSecukinumab showed consistent and sustained efficacy in clearing nail psoriasis in patients with psoriatic arthritis, with or without axial manifestations, irrespective of severity of nail involvement. Reduction of nail disease was also associated with response across all musculoskeletal and skin manifestations of psoriatic arthritis. |
| spellingShingle | Reich, K Baraliakos, X Coates, LC Elewski, B Bao, W Kasparek, T Gaillez, C Pournara, E Aassi, M Perella, C Gottlieb, AB Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analysis from phase 3 trials in patients with psoriatic arthritis |
| title | Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analysis from phase 3 trials in patients with psoriatic arthritis |
| title_full | Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analysis from phase 3 trials in patients with psoriatic arthritis |
| title_fullStr | Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analysis from phase 3 trials in patients with psoriatic arthritis |
| title_full_unstemmed | Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analysis from phase 3 trials in patients with psoriatic arthritis |
| title_short | Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analysis from phase 3 trials in patients with psoriatic arthritis |
| title_sort | secukinumab demonstrates high and sustained efficacy in nail psoriasis post hoc analysis from phase 3 trials in patients with psoriatic arthritis |
| work_keys_str_mv | AT reichk secukinumabdemonstrateshighandsustainedefficacyinnailpsoriasisposthocanalysisfromphase3trialsinpatientswithpsoriaticarthritis AT baraliakosx secukinumabdemonstrateshighandsustainedefficacyinnailpsoriasisposthocanalysisfromphase3trialsinpatientswithpsoriaticarthritis AT coateslc secukinumabdemonstrateshighandsustainedefficacyinnailpsoriasisposthocanalysisfromphase3trialsinpatientswithpsoriaticarthritis AT elewskib secukinumabdemonstrateshighandsustainedefficacyinnailpsoriasisposthocanalysisfromphase3trialsinpatientswithpsoriaticarthritis AT baow secukinumabdemonstrateshighandsustainedefficacyinnailpsoriasisposthocanalysisfromphase3trialsinpatientswithpsoriaticarthritis AT kasparekt secukinumabdemonstrateshighandsustainedefficacyinnailpsoriasisposthocanalysisfromphase3trialsinpatientswithpsoriaticarthritis AT gaillezc secukinumabdemonstrateshighandsustainedefficacyinnailpsoriasisposthocanalysisfromphase3trialsinpatientswithpsoriaticarthritis AT pournarae secukinumabdemonstrateshighandsustainedefficacyinnailpsoriasisposthocanalysisfromphase3trialsinpatientswithpsoriaticarthritis AT aassim secukinumabdemonstrateshighandsustainedefficacyinnailpsoriasisposthocanalysisfromphase3trialsinpatientswithpsoriaticarthritis AT perellac secukinumabdemonstrateshighandsustainedefficacyinnailpsoriasisposthocanalysisfromphase3trialsinpatientswithpsoriaticarthritis AT gottliebab secukinumabdemonstrateshighandsustainedefficacyinnailpsoriasisposthocanalysisfromphase3trialsinpatientswithpsoriaticarthritis |